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Abstract
Background: The use of artemisinin-based combination therapy (ACT) is currently recommended for treating
uncomplicated malaria. The objective was to assess the efficacy and safety of repeated administrations of two
fixed-dose presentations of ACT - artesunate plus amodiaquine (ASAQ) and artemether-lumefantrine (AL) - in
subsequent episodes of Plasmodium falciparum malaria.
Methods: A randomized comparative study was conducted in a rural community of central Senegal from August
2007 to January 2009. Children and adults with uncomplicated P. falciparum malaria were randomized to receive
open-label ASAQ once daily or AL twice daily for three days. Drug doses were given according to body weight.
Treatments for first episodes were supervised. For subsequent episodes, only the first intake of study drug was
supervised. ECGs and audiograms were performed in patients ≥12 years of age. Primary outcome was adequate
clinical and parasitological response rate (ACPR) after polymerase chain reaction (PCR) correction on day 28 for the
first episode.
Results: A total of 366 patients were enrolled in the two groups (ASAQ 184, AL 182) and followed up during two
malaria transmission seasons. In the intent-to-treat population, PCR-corrected ACPRs at day 28 for the first episode
were 98.4% and 96.2%, respectively, in the ASAQ and AL groups. For the per-protocol population (ASAQ 183, AL
182), PCR-corrected ACPRs at day 28 for the first episode were 98.9% and 96.7%, respectively. A 100% ACPR rate
was obtained at day 28 in the 60 and four patients, respectively, who experienced second and third episodes.
Treatment-related adverse events were reported in 11.7% of the patients, without significant differences between
the two groups. A better improvement of haemoglobin at day 28 was noted in the ASAQ versus the AL group
(12.2 versus 11.8 g/dL; p = 0.03). No sign of ototoxicity was demonstrated. A prolongation of the QTc interval was
observed in both groups during treatment with no clinical consequence.
Conclusions: Study results confirmed the satisfactory efficacy and safety profile of ASAQ and AL. Moreover, in
patients who were treated at least twice, repeated administration of ASAQ or AL did not identify any major safety
issues.
Trial registration: ClinicalTrials.gov identifier NCT00540410.
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Malaria is a leading cause of morbidity and mortality,
particularly in children, in sub-Saharan Africa, the infec-
tion being due to Plasmodium falciparum in 98% of
cases [1]. It is estimated that in 2008, among the chil-
dren living in Africa, there were 247 million cases of
malaria. Nearly one million of these children died of the
disease, making malaria responsible for one-fifth of all
childhood deaths in Africa. In Senegal alone, two million
cases of malaria were recorded in 2005, and 2000 deaths
were attributed to the disease [2].
The World Health Organization (WHO) first recog-
nized the benefit of oral artemisinin-based combination
therapy (ACT) compared with oral monotherapy for the
treatment of uncomplicated P. falciparum malaria in
2001 [3], and the 2006 guidelines recommended the use
of ACT [4]. This recommendation has been reiterated
in the second edition of its guidelines published in 2010
[5]. The rationale for this recommendation is that the
artemisinin derivative very rapidly reduces the parasite
biomass, thus enabling lasting exposure of the few
remaining parasites to a high concentration of the other
agent in the combination [6]. The artemisinin derivative
may also prevent transmission of P. falciparum and thus
limit the spread of resistance [7]. The use of ACT was
instigated in Senegal in 2006 as part of the National
Malaria Control Programme (NMCP), which involved
both prevention and prompt treatment. This policy deci-
sion was supported by the finding that ASAQ used over
a six-year period remained highly effective in a region of
Senegal where chloroquine resistance exceeded 60% [8].
Following this decision, a large reduction in the number
of confirmed malaria cases was seen, and this approach
is considered to be an important contributory factor in
the 30% reduction in all-cause mortality that occurred
between 2005 and 2009 in Senegal among children
under five years of age [2].
In clinical trials conducted in Africa, oral once-daily
artesunate plus once-daily amodiaquine (ASAQ) given
for three days has been shown to be as effective and as
well tolerated as comparators in the treatment of
uncomplicated P. falciparum malaria [9-14]. The use of
a fixed-dose combination (FDC) helps eliminate the risk
of only one of the two drugs being taken, which may be
an especially important consideration in children [15].
The benefits of a FDC therapy have been recognized by
the WHO, being considered to be preferable to blister
co-packaged or loose tablet combinations for the treat-
ment of malaria [5]. The Artesunate Amodiaquine Win-
throp
® FDC (Coarsucam
®, Sanofi Aventis) was
developed in 2007 by Sanofi-Aventis’ Impact Malaria in
partnership with the Drugs for Neglected Disease initia-
tive, a non-profit-making drug research and
development organization. ASAQ and artemether-lume-
fantrine (AL) (Coartem
®, Novartis) are two co-formu-
lated ACTs to be granted “prequalified” status by the
WHO, with the aim of ensuring that active and effective
anti-malarial treatment reaches those people in need. In
Senegal, the NMCP has recommended the use of either
ASAQ or AL as first-line treatment since 2006, when it
became available in the public sector. Since then, more
than 1.5 million treatments have been administered.
People living in areas where the disease is endemic
often experience more than one malaria attack in a sin-
gle season, depending on the local epidemiological pro-
file. The aim of this randomized, open-label study was
to compare the clinical and parasitological efficacy, in
addition to clinical safety, laboratory profile, QTc and
auditory safety, of repeated administration of ASAQ
FDC versus AL FDC for the treatment of recurrent epi-
sodes of uncomplicated P. falciparum malaria in both
adults and children.
Methods
Study design
The study was conducted at a single centre in Senegal
over two periods of malaria transmission. The study site
was the rural community of Keur Soce, which is 200 km
south-east of Dakar. Residents in this community had
previously shown a strong commitment to the treatment
of malaria and recognized the role of the community
health workers who visited the patients weekly. On day
0, patients presenting with symptoms of uncomplicated
P. falciparum were randomized to open-label oral treat-
ment with either once-daily ASAQ FDC or twice-daily
AL FDC taken on three consecutive days (days 0-2)
under the supervision of a dedicated nurse; clinical and
parasitological investigators were not aware of the type
of allocated ACT. ASAQ was shipped to Senegal by
Sanofi Aventis, and AL was purchased from a wholesa-
ler in Dakar. The once-daily dose of ASAQ was adjusted
according to patient’s body weight: 5.0-8.9 kg, one 25.0/
67.5-mg tablet per day; 9.0-17.9 kg, one 50/135-mg
tablet; 18.0-35.9 kg, one 100/270-mg tablet; and ≥36 kg,
two 100/270-mg tablets. The number of 20/120-mg AL
FDC tablets taken daily was adjusted according to body
weight: 5.0-14.9 kg, one tablet twice daily; 15.0-24.9 kg,
two tablets twice daily; 25.0-34.9 kg, three tablets twice
daily; and ≥35 kg, four tablets twice daily. Tablets were
taken with a small volume of potable water. If the
patient vomited within 30 minutes of tablet intake, the
dose was repeated. In the event of a second vomiting
episode, the patient was withdrawn and received quinine
in compliance with the directives of the NMCP. In addi-
tion, paracetamol 60 mg (maximum daily dose 3 g) was
permitted for the treatment of fever. Patients were
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follow-up on days 7, 14 and 28. Patients failing treat-
ment within the 14 days of the initiation of study-drug
treatment received quinine in accordance with the
NMCP directive. Residents of the villages within the
community were regularly visited by the community
health workers. Patients with fever and sickness were
asked to attend the clinic. Any patient identified as pre-
senting with a recurrent episode occurring more than
14 days after the first episode received the same treat-
ment as taken for the first episode (but with only the
first drug intake being supervised). A recommendation
to take food immediately after the unobserved ACT
intake was given by the nurse in charge of treatment
allocation. In the event of vomiting within the 30 min-
utes of unsupervised medication intake, the patient was
advised to return to the centre in order to be re-admi-
nistered the same dose. Patients were evaluated at days
0, 3, 7, 14 and 28. The protocol complied with recom-
mendations of the 18th World Health Congress (Hel-
sinki, 1964), and all applicable amendments, conformed
to the laws and regulations of Senegal and received local
Ethics Committee approval. The study obtained the
ethical approval from the Conseil National de Recherche
en Santé (National Council for Health Research) of
Senegal on 7 August 2007.
Patients
Finger-prick blood samples were obtained using a vacci-
nostyle and were prepared and stained with May-Grün-
wald-Giemsa. Thick smears were used to determine
parasite density, and thin smears were used to charac-
terize the parasite species. The inclusion criteria were:
P. falciparum infection with a blood parasite density
>1000 asexual forms/μL on day 0 of first episode of
malaria; body weight ≥5 kg; axillary temperature ≥37.5°
C (measured using an electronic thermometer on day 0
or history of fever within the previous 24 hours (not
required if treatment failure according to the WHO
classification [5] occurred >14 days after a previous epi-
sode); and provision of written informed consent of
adult patients or that of a parent or guardian for sub-
jects <18 years of age. The presence of any of the fol-
lowing excluded patients from the study: pregnancy
confirmed by a positive urine test; history of hepatic
and/or haematological impairment during treatment
with amodiaquine; family history of congenital QTc pro-
longation or sudden death, or any clinical condition
known to prolong the QTc interval (e.g., cardiac
arrhythmia with significant bradycardia or severe cardiac
failure); allergy to any component of the study drugs;
presence of one or more serious or clinical danger signs
of malaria; receipt of medication metabolized by or inhi-
biting CYP2D6; receipt of medication known to prolong
the QTc interval; electrolyte imbalances; and/or receipt
of ASAQ or AL at an appropriate dosage ≤14 days
before inclusion in this study.
PCR analysis
DNA was extracted from blood collected on 3MM
®
Whatman filter paper by the methanol method [16].
Extracted DNA from each sample was used immediately
for PCR by a two-step amplification scheme, with the
product of the outer PCR being used as the template for
the nested-PCR for both msp1 and msp2. For msp1,t h e
primers used in the first amplification were conserved
among all isolates. Allelic family-specific primers used in
the second amplification reaction for block2 of msp1
corresponded to msp1 types MAD20, KI and RO33.
PCR amplifications of msp2 genes were performed as
described by Foley et al [17]. The msp2 nested-PCR
product was subjected to site-specific restriction diges-
tion using Haemophilus influenza 1 enzyme to distin-
guish between type FC27 and 3D7 alleles.
Electrophoresis was performed on the PCR products,
using 100 base pair ladders to estimate the sizes of the
DNA fragments.
Study endpoints
The primary efficacy endpoint was adequate clinical and
parasitological response (ACPR), as defined by WHO
[18], of ASAQ compared with AL after polymerase
chain reaction (PCR) correction at day 28 of the first
episode. The secondary efficacy endpoints were: ACPR
efficacy at day 14 of first episode; time to parasite clear-
ance after the first episode; time to fever resolution after
first episode; ACPR at days 14 and 28 of second and
any subsequent episodes; proportion of apyretic patients
at day 3 of second and any subsequent episodes; propor-
tion of gametocytes carriers and proportion of patients
free from parasite at day 3 of second and any subse-
quent episodes. The nature and intensity of all adverse
events were assessed by the investigator at each visit
until day 28 by questioning the patient/parent/guardian.
All events were recorded as treatment-emergent if they
occurred between day 0 and day 28. Some adverse
events were defined as of special interest as described in
the study protocol, together with the date of onset. An
adverse event of special interest is defined as one that
requires appropriate continuous monitoring and could
necessitate additional examinations for it to be charac-
terized and understood. Clinical laboratory tests and
vital signs after each episode were also monitored. Veni-
puncture samples collected on days 0, 7 and 28 were
analysed for haematological parameters (haemoglobin
and platelet, neutrophil and leucocyte counts) and bio-
chemical parameters (blood glucose, blood creatinine,
total bilirubin and alanine aminotransferase). In
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cia formula from an ECG (Philips Trim III) and was
assessed on day 0 before dosing and on day 3 of the
first episode in patients aged ≥12 years. Auditory evalua-
tion was performed by determining the difference (in
decibels) observed between the hearing threshold
obtained for each ear and octave range using an
AUDIOSCAN
® (Essilor International; Vincennes,
France) high-resolution automatic Békésy audiometry
method, involving level frequency sweeps and between 5
and 16 kHz, performed in subjects without a history of
otological pathology and aged ≥12 years after the first
and any subsequent episode on day 0 before dosing and
on day 3, and was planned to be repeated on day 28 if
any abnormality had been detected on day 3. Both QTc
prolongation and audiometric assessment were per-
formed by independent investigators. Treatment compli-
ance was determined by tablet count of returned
medication after the second and any subsequent epi-
sodes. All adverse events were coded using the Medical
Dictionary for Regulatory Activities, and severity of clin-
ical laboratory abnormalities was graded according to
the Division of Microbiology and Infectious Disease
Toxicity Tables (May 2001).
Statistical methods
Non-inferiority of ASAQ compared with AL was tested
by calculating the 95% confidence interval (CI) of the
difference observed in the success rates between both
treatment groups, with a 2.5% (one-sided) significance
level (non-inferiority delta of 5%). It was established that
a total of 174 patients would need to be enrolled based
on a previous AL study that reported a treatment failure
rate of 2.7% [19]. Allowing for 15% incidence of prema-
ture withdrawals, the total number of patients required
would be 200 per treatment group.
Statistical analyses were performed using SAS
® soft-
ware package (version 8.2: SAS Institute Inc., Cary, NC,
USA). Analysis of the primary efficacy endpoint was
conducted in the intent-to-treat population (i.e., all ran-
domized patients having received at least one treatment
dose). Analysis of the efficacy was also performed in the
per-protocol population. The non-inferiority of ASAQ
versus AL was determined by calculating the 95% CI of
the difference observed in the PCR-corrected ACPR
between the two treatment groups, with a 2.5% (one-
sided) significance level (non-inferiority difference of
5%). Time to the next episode was analysed using
Kaplan-Meier survival plots. The statistical significance
o ft h em e a nd i f f e r e n c eb e t ween treatment groups was
determined using Student t-test, or Wilcoxon rank test
when distribution was not normal. Percentage responses
were analysed by the chi
2 test or Fisher’s non-parametric
test when the number of patients was less than five.
Wilcoxon rank test was used to compare total bilirubin
and alanine aminotransferase levels between treatment
groups during the first episode.
Results
Patient characteristics
A total of 839 patients were screened. Reasons for non-
enrolment, in addition to failure to meet the inclusion
criteria and/or the presence of an exclusion criterion,
were unwillingness to commit to two years’ follow-up
and logistical problems in visiting the health centre. A
consort flow diagram is shown in Figure 1, which sum-
marizes the withdrawals and the number of patients
experiencing second and third episodes in the 366 ran-
domized patients. Because of the vigilance of the com-
munity health workers, no patient was lost to follow-up.
The baseline characteristics of the 366 patients enrolled
and randomized to either ASAQ FDC (n = 184) or AL
F D C( n=1 8 2 )w e r ec o m p a r a b l e( T a b l e1 ) .N od i f f e r -
ences in vital signs, malaria signs and symptoms (pain,
headache, nausea, chills, perspiration, weakness, anor-
exia, jaundice, dizziness, dehydration and splenomegaly),
or axillary temperatures were apparent in the two treat-
ment groups. The predominant symptoms were mild
weakness and anorexia.
Compliance
Compliance with study-drug medication, which was
taken under supervision for the treatment of the first
episode, was confirmed as 100%. Compliance with
treatment for the second episode was 98.3%. One
patient took only one of the two tablets of AL required
to be taken in the evening of day 0, but this mistake
was identified by a local guide visiting the patient’s vil-
lage in the morning of day 1, and the need to take two
AL tablets was explained again. This patient took two
AL tablets twice daily for the remainder of this treat-
ment course.
Clinical and parasitological efficacy: primary endpoint
The PCR-corrected ACPR rate at follow-up on day 28
after the first malaria episode for the ASAQ group was
98.4% versus 96.2% for the AL group in the intent-to-
treat population (Table 2). The 95% CI of the difference
in the PCR-corrected ACPR rates in the intent-to-treat
population for ASAQ and AL was -0.011, 0.056 in the
overall population, with the non-inferiority of ASAQ
versus AL being demonstrated in the overall population
and in patients aged <12 and ≥12 years. The ACPR
rates were comparable in the per-protocol population
(Table 3), with the 95% CI of the difference in the PCR-
corrected ACPRs for ASAQ and AL being (-0.008,
0.052) in the overall population. Kaplan-Meier analysis
did not identify any significant difference up to day 28
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ment groups (p = 0.20).
Clinical and parasitological efficacy: secondary endpoints
Treatment response rates before PCR correction are
summarized in Table 4. The calculated 95% CI of the
difference of the ACPR rates before PCR correction for
ASAQ and AL confirmed that the efficacy of ASAQ
was non-inferior to that of AL in the intent-to-treat
(-0.020, 0.065) and per-protocol (-0.022, 0.067) patient
populations The ACPR rates before PCR correction at
day 28 were 100% in both the intent-to-treat and per-
protocol populations experiencing a second episode
following treatment with either ASAQ (both popula-
tions n = 27) and AL (n = 33 and 23, respectively). For
the four patients experiencing a third episode, the
ACPR before PCR correction at day 28 were 100%
following treatment with either ASAQ (n = 2) or AL
(n = 2).
In the ASAQ and AL groups, 19.6% and 25.3%,
respectively, received paracetamol for fever at the discre-
tion of the physician. Fever resolution was rapid and all
patients were apyretic by day 3 of the first episode. The
mean time to parasite clearance was 1.7 ± 0.5 days in
both the ASAQ and AL treatment groups (p = 0.10).
The majority of patients (97% in both groups) were
parasite-free at day 2 of the first episode, and all patients
were parasite-free at day 3 (Figure 2). Although the pro-
portion of gametocyte carriers in the ASAQ group was
higher than that in the AL group at day 2 (8.2% versus
2.7%, p = 0.02), day 3 (8.2% versus 2.8%, p = 0.02) and
day 7 (6.6% versus 1.1%, p = 0.01), no gametocyte car-
rier was detected in either treatment group at day 28.
Mean measured haemoglobin blood levels according
to treatment groups for the first treated episode of
malaria are shown in Figure 3. Haemoglobinaemia
increased by 1.32 ± 2.2 and 0.94 ± 2.2 g/dL, respectively,
at day 28 in the ASAQ and AL groups. The difference
Figure 1 Disposition of patients according to the number of malarial episodes experienced in a randomized open-label study:
comparing treatment with fixed-dose combinations of artesunate plus amodiaquine (ASAQ) and artemether plus lumefantrine (AL).
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cant (p = 0.03).
A nA C P Rw a so b s e r v e da td a y2 8i n6 0a n df o u r
patients, respectively, who presented with a second and
a third episode of uncomplicated malaria, with all
patients parasite-free at day 3. The mean time to first
recurrence (181.3 ± 165.2 days) was not significantly dif-
ferent between the two treatments (p = 0.35). Of the 27
ASAQ patients experiencing a second episode, in 33%
this occurred on or before day 15 after the end of the
first episode, in 19% between day 16 and 41, and recur-
rence in remaining 46% of patients occurred 200 days
or later after the first episode. The corresponding per-
centages for the 33 AL patients were 39%, 3% and 58%.
The ACPRs before PCR correction at day 28 were
100% in both the intent-to-treat and per-protocol popu-
lations experiencing a second episode following treat-
ment with either ASAQ (both populations n = 27) and
AL (n = 33 and 23, respectively). For the four patients
experiencing a third episode, ACPR rates before PCR
correction at day 28 were 100% following treatment
with ASAQ (n = 2) or AL (n = 2),
Safety
The incidence of adverse events throughout the study
period is summarized in Table 5. A woman treated with
AL had a positive pregnancy test at day 28. She sponta-
neously aborted 8 weeks after her last menstruation.
There were insufficient data to establish whether or not
the pregnancy and miscarriage were related to AL. The
two serious adverse events (severe coma and severe con-
vulsions), both occurring in patients aged <12 years,
were not considered related to treatment with ASAQ or
AL. Adverse events associated with the blood and lym-
phatic, gastrointestinal and nervous systems were the
most common ones considered by the investigators to
be treatment related, occurring at frequencies of 5.2%,
4.1% and 2.5%, respectively, throughout the study
Table 1 Patient characteristics of the intent-to-treat
population
a
Characteristic ASAQ
(n = 184)
AL
(n = 182)
p-
value
Sex, n (%)
Male 102 (55.4) 98 (53.8) 0.76
b
Age, years
Mean ± SD 11.94 ± 10.52 11.75 ± 9.17 0.67
c
Range 0.8-65.0 1.2-60.0
<12 years, n (%) 101 (54.9) 100 (54.9) 0.99
b
Weight, kg
Mean ± SD 29.55 ± 16.11 31.08 ± 17.34 0.59
c
Range 9.0-89.0 7.6-77.2
BMI, kg/m
2
Mean ± SD 14.87 ± 3.11 14.99 ± 3.22 0.58
c
Range 10.0-29.7 9.8-27.4
Parasite density, asexual
forms/μl
Geometric mean 32383.9 ±
37362
31713.7 ±
37253
0.716
c
Range 1034-195764 1016-195837
Gametocyte carriers, n (%) 7 (3.8) 2 (1.1) 0.174
d
Blood haemoglobin, g/dL
Mean ± SD 10.9 ± 2.3 10.8 ± 2.5 0.85
e
Range 5.8-15.8 5.5-18.2
aAll randomized patients receiving at least one dose of study drug (patients
vomiting twice after receipt of first dose were excluded);
bChi
2 test;
cWilcoxon
rank test;
dFisher’s exact test;
eStudent t-test.
Table 2 Treatment responses at day 28 after PCR correction for the first episode in the intent-to-treat patient
population
a
Treatment response ASAQ AL Total
Number (%)
Overall population (n = 184) (n = 182) (n = 366)
Late clinical failure 0 (0.0) 3 (1.6) 3 (0.8)
Late parasitological failure 1 (0.5) 2 (1.1) 3 (0.8)
Adequate clinical and parasitological response 181 (98.4) 175 (96.2) 356 (97.3)
Not applicable 2 (1.1) 2 (1.1) 4 (1.1)
<12 years old (n = 101) (n = 100) (n = 201)
Late clinical failure 0 (0.0) 3 (3.0) 3 (1.5)
Late parasitological failure 1 (1.0) 1 (1.0) 2 (1.0)
Adequate clinical and parasitological response 98 (97.0) 95 (95.0) 293 (96.0)
Not applicable 2 (2.0) 1 (1.0) 3 (1.5)
≥12 years old (n = 83) (n = 82) (n = 165)
Late parasitological failure 0 (0.0) 1 (1.2) 1 (0.6)
Adequate clinical and parasitological response 83 (100.0) 80 (97.6) 163 (98.8)
Not applicable 0 (0.0) 1 (1.2) 1 (0.6)
aAll randomized patients receiving at least one dose of study drug (patients vomiting twice after receipt of first dose were excluded).
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drug treatment occurring throughout the study accord-
ing to intensity is provided in Table 6. There were only
four treatment-related adverse events occurring during
recurrent episodes, which were mild, and the patients
recovered rapidly. Treatment-related anaemia, which
occurred during the first episode in five patients aged
<12 years and in one patient aged ≥12 years treated
with ASAQ, and in four patients aged <12 years and in
four patients aged ≥12 years in the AL group, was gen-
erally mild in intensity. Recovery usually occurred with
or without iron-based treatment within 3 weeks. Persis-
tent anaemia was detected in three patients (one in
ASAQ group and two in AL group) with concomitant
infections or infestations. No anaemia was detected in
patients treated for subsequent episodes of malaria. The
severe neutropenia (<400 neutrophils/mm
3 in children
and <750 neutrophils/mm
3 in adults) observed in 10
patients (four in the ASAQ group, six in the AL group)
was considered to be treatment related in five patients;
all were ≥12 years of age. Recovery by day 28 was
observed in two patients, and neutrophil counts subse-
quently returned to normal in the remaining patients.
Gastrointestinal events (mild, transient abdominal pain
and/or vomiting) occurred in nine (4.9%) ASAQ- and
seven (3.7%) AL-treated patients, and were more fre-
quent in patients aged ≥12 years old. Transient mild
sleep disturbances occurred in seven (3.8%) patients in
t h eA S A Qg r o u pa n dw e r em o r ec o m m o ni np a t i e n t s
aged <12 years. These disturbances were resolved within
1 or 2 days.
No differences in haematological or renal laboratory
findings were detected in the two treatment groups.
Similarly, no differences in total bilirubin and serum ala-
nine aminotransferase were recorded (Table 7).
Audiometric measurements were performed in 167
patients (74 female patients aged 19.4 ± 10.8 years, and
93 male patients aged 18.8 ± 10.7 years) during the first
Table 3 Treatment responses at day 28 after PCR correction for the first episode in the per- protocol patient
population
a
Treatment response ASAQ AL Total
Number (%)
Overall population (n = 183) (n = 181) (n = 364)
Late clinical failure 0 (0) 3 (1.7) 3 (0.6)
Late parasitological failure 1 (0.5) 2 (1.1) 3 (0.8)
Adequate clinical and parasitological response 181 (98.9) 175 (98.7) 356 (97.8)
Not applicable 1 (0.5) 1 (0.6) 2 (0.5)
<12 years old (n = 100) (n = 100) (n = 200)
Late clinical failure 0 (0.0) 3 (3.0) 3 (1.5)
Late parasitological failure 1 (1.0) 1 (1.0) 2 (1.0)
Adequate clinical and parasitological response 98 (98.0) 95 (95.0) 193 (96.5)
Not applicable 1 (1.0) 1 (1.0) 2 (1.0)
≥12 years old (n = 83) (n = 82) (n = 164)
Late parasitological failure 0 (0.0) 1 (1.2) 1 (0.6)
Adequate clinical and parasitological response 83 (100.0) 80 (97.6) 163 (99.8)
aAll patients who completed the study protocol without any major protocol deviation in treatment evaluation.
Table 4 Treatment responses at day 28 before PCR correction for the first episode in the intent-to-treat (ITT) and per-
protocol (PP) patient populations
Treatment response ASAQ AL Total
Number (%)
ITT population (n = 184) (n = 182) (n = 366)
Late clinical failure 1 (0.5) 5 (2.7) 6 (1.6)
Late parasitological failure 4 (2.2) 4 (2.2) 8 (2.2)
Adequate clinical and parasitological response 177 (96.2) 171 (94.0) 348 (95.1)
Not applicable 2 (1.1) 2 (1.1) 4 (1.1)
PP population (n = 183) (n = 181) (n = 364)
Late clinical failure 1 (0.5) 5 (2.8) 6 (1.6)
Late parasitological failure 4 (2.2) 4 (2.2) 8 (2.2)
Adequate clinical and parasitological response 177 (96.7) 171 (94.5) 348 (95.6)
Not applicable 1 (0.5) 1 (0.6) 2 (0.5)
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Page 7 of 12treated malaria episode and in 12 patients experiencing
a second episode. Hearing thresholds measured on days
3 and 28 did not show any significant variation com-
pared with that measured prior to treatment administra-
tion on day 0, with no difference between ASAQ and
either dose of AL.
ECGs were recorded in 171 patients on day 0 and in
153 patients on day 3. Marked prolongations of the
QTc interval (>20 ms) were observed in both treatment
groups between day 0 and day 3 (Figure 4). The mean
increase in the QTc interval was 22.4 ms in the AL
group compared with 33.2 ms in the ASAQ group, and
the difference between these treatments was statistically
significant (p = 0.011). Details of ECG results are
summarized in Table 8. Unfortunately, planned control
at day 28 was not performed in a majority of cases due
to logistical problems in transmitting the ECGs to the
off-site evaluator. However, the ECG modifications at
day 3 had no clinical significance or any impact; hence,
the investigators did not perform an ECG control at day
28.
Discussion
ACT is now regarded as the first-line treatments for
uncomplicated P. falciparum malaria in most malaria-
endemic countries, as advocated by the WHO [4,5], and
is gaining widespread acceptance in both the private and
public sectors for the treatment of adults and children
Figure 2 Effects of 3 days’ treatment with fixed dose combination of artesunate plus amodiaquine (ASAQ) or artemether plus
lumefantrine (AL) started on day 0 of the first episode of malaria on the rate of parasite clearance.
Figure 3 Blood haemoglobin levels following treatment with a fixed-dose combination of artesunate plus amodiaquine (ASAQ) or
artemether plus lumefantrine (AL) for the first malaria episode in the intent-to-treat population.
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Page 8 of 12in malaria-endemic African countries. ACT, such as
ASAQ, can reduce the parasite biomass rapidly and sub-
stantially, resulting in fast parasite clearance and resolu-
tion of clinical symptoms. Together with its efficacy
against multidrug-resistant P. falciparum, its ability to
reduce gametocyte carriage and to help reduce transmis-
sion of resistant alleles makes ACT an essential tool in
malaria control and the fight to eliminate the disease
[6]. The efficacy of ASAQ given as a FDC is supported
by findings of clinical studies performed in locations
throughout sub-Saharan Africa [12,13].
Pharmacovigilance, involving the detection, assess-
ment, understanding and prevention of adverse effects
or any other drug-related problems, of ACT has been
advocated to establish its safety in African populations.
This is especially important because such treatments
may be repeatedly used in treating recurrent episodes in
those geographical areas where the disease is endemic.
Most notably, there have been concerns about the
potential of AQ monotherapy to cause haematological
and hepatic toxicity when used prophylactically [20].
Post-marketing safety usuallyr e l i e so nt h es p o n t a n e o u s
reporting of adverse reactions, but is often incomplete
in the developing countries of sub-Saharan Africa due
to an inadequate safety-monitoring infrastructure [21].
However, collaboration between academic investigators,
drug companies and governments can assist in the phar-
macovigilance of new anti-malarial drugs.
FDCs are important candidates for pharmacovigilance,
given their potential advantages in the management of
malaria. The FDC of AL was the first fixed-dose ACT to
be approved, after the demonstration of its efficacy in
the treatment of uncomplicated P. falciparum malaria
when administered twice daily for three days. Subse-
quently, the FDC of ASAQ became available. This pro-
duct only requires a three-day dosing regimen, but also
offers the added convenience of once-daily dosing.
The present collaborative Phase IV study was con-
ducted in a rural area of Senegal where malaria is ende-
mic and highly seasonal, occurring between September
and December, with an entomological inoculation rate
of between 9 and 12 during that period (Faye O, unpub-
lished data). The vector responsible for malaria trans-
mission is Anopheles gambiae. In order to increase the
possibility of repeat malaria episodes, the study was con-
ducted over two periods of malaria transmission.
T h ep r e s e n ts t u d yc o n f i r m e dt h a tt h eo n c e - d a i l yd o s -
ing regimen of the ASAQ FDC did not compromise
Table 5 Adverse events (AEs) occurring during the whole
study period
ASAQ
(n = 184)
AL
(n = 182)
Emergent AEs 60 60
Treatment-related AEs (%)
a 32 (53.3) 21 (35.0)
AE of special interest
b (%) 4 (6.7)
c 4 (6.7)
c
Pregnancy (%) 0 1 (1.7)
c
Serious AEs (%) 1 (1.7) 1 (1.7)
Deaths 0 0
AE intensity (%)
Mild 45 (75.0) 44 (73.3)
Moderate 13 (21.7) 15 (25.0)
Severe 2 (3.3) 1 (1.7)
Overall study (%)
Patients with at least one AE 47 (25.5) 47 (25.8)
Patients with at least one
treatment-related AE
26 (14.1) 17 (9.3)
Patients with at least one SAE and
permanent study withdrawal due
to AE
1 (0.5) 1 (0.5)
First episode (%)
Patients with at least one AE 43 (23.4) 41 (22.5)
Patients with at least one SAE and
permanent study withdrawal due
to AE
1 (0.5) 1 (0.5)
Second episode (%)
Patients with at least one AE 4 (14.8) 8 (24.2)
aPercentage of emergent events.
bNeutropenia <400 neutrophils/mm
3 in
children or <750 neutrophils/mm
3 in adults.
cOccurred during 28 days of first
episode evaluation.
Table 6 Incidence of treatment-related adverse events occurring during the whole study
a
Disorder type ASAQ
(n = 184)
AL
(n = 182)
Number (%)
Mild Moderate Severe Mild Moderate Severe
Blood and lymphatic 7 (3.8) 2 (1.1) 1 (0.5) 8 (4.4) 2 (1.1) 0 (0.0)
Gastrointestinal 7 (3.8) 2 (1.1) 0 (0.0) 6 (3.3) 1 (0.5) 0 (0.0)
Nervous 7 (3.8) 1 (0.5) 0 (0.0) 1 (0.5) 0 (0.0) 0 (0.0)
Skin, subcutaneous tissue 2 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0)
Respiratory, thoracic, mediastinal 2 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Hepatobiliary 1 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
General 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0)
aPercentage of patients experiencing an event/total safety population.
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Page 9 of 12efficacy. The PCR-corrected ACPR rate - the primary
efficacy endpoint - achieved with ASAQ FDC was non-
inferior to that of the AL FDC administered twice daily.
The resolution of fever and elimination of parasites was
rapid with either treatment. Patients who are asympto-
matic, however, may remain gametocyte carriers and
serve as an important reservoir for further disease trans-
mission [22]. Without eradication of gametocytes,
asymptomatic infection may persist beyond the rainy
season and perpetuate disease transmission into the
next season [23]. The relatively small number of patients
returning with a second, and particularly a third, malaria
episode suggests that there may have been an effective
eradication of sexual parasites in this study. Both FDCs
proved equally effective in treating the second and third
episodes.
Adherence to medication is fundamental to the suc-
cessful treatment of malaria and is assisted by use of a
FDC. Direct supervision ensures total treatment compli-
ance by the patient, as was the case for the treatment of
the first episode in this study. In day-to-day practice,
however, this approach is not feasible and the health-
care worker is reliant on the patient understanding and
following instructions. Therefore, the simpler the regi-
men, the greater the likelihood is of total compliance.
Although there is potential for poor adherence to dosing
that involves taking more than one tablet on each occa-
sion in the absence of supervision, there was only one
patient in this study who did not take the full dose
when unsupervised. However, the mistake made by this
patient was quickly identified (only one dose was
missed) and the problem was rectified. Compliance is
likely to be poorer if a patient is not participating in a
trial or is not being closely monitored. The simplicity of
dosing using a FDC may also be particularly advanta-
geous when treating children [24].
The clinical safety in terms of adverse events and clin-
ical laboratory findings was found to be comparable for
ASAQ and AL in our study, with no evidence of haema-
tological and hepatic toxicity associated with the use of
Table 7 Summary of changes in total bilirubin and
alanine aminotransferase during the first episode
ASAQ AL p-value
Total bilirubin mg/dL)
Day 0 (n = 184) (n = 182)
Mean ± SD 1.46 ± 0.99 1.50 ± 1.51 0.796
Range 0.02-5.52 0.01-17.27
Day 7 (n = 182) (n = 180)
Mean ± SD 0.83 ± 1.45 0.80 ± 1.04 0.825
Range 0.03-19.25 0.04-13.18
Day 28 (n = 181) (n = 175)
Mean ± SD 0.60 ± 0.35 0.80 ± 1.04 1.000
Range 0.01-2.33 0.03-2.57
ALT (UI/L)
Day 0 (n = 184) (n = 182)
Mean ± SD 29.2 ± 30.0 27.8 ± 29.8 0.505
Range 2-199 1-217
Day 7 (n = 183) (n = 181)
Mean ± SD 22.4 ± 15.7 25.1 ± 27.4 0.877
Range 1-95 1-218
Day 28 (n = 181) (n = 175)
Mean ± SD 20.9 ± 14.9 19.5 ± 15.9 0.053
Range 1-110 3-99
Figure 4 QTcF at day 0 and day 3 after treatment with a fixed-dose combination of artesunate plus amodiaquine (ASAQ) or
artemether plus lumefantrine (AL) for the first malaria episode in the intent-to-treat population.
Table 8 Summary of ECG changes
ASAQ AL
Number of episodes
QTcF interval at day 3 (n = 77) (n = 77)
>500 ms 0 0
480-499 ms 0 0
450-479 ms 3 1*
Change in QTcF from baseline (day 3/day 0) (n = 76) (n = 77)
≥60 ms 9 6
30-59 ms 30 23
* This patient presented with a QTcF > 450 ms at baseline.
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400 patients, treatment-related adverse events were
recorded in <12% of the patients. The incidences of
these events were comparable with the ASAQ and the
AL FDCs, with most events being mild or moderate in
intensity. The persistent anaemia observed in three chil-
dren was probably attributable to helminthiasis as preva-
lence of intestinal parasites in children is high in this
area of Senegal. Although a relatively small proportion
of patients received a second or third course of treat-
ment for subsequent episodes, there was no evidence of
any difference in adverse event reporting with repeated
use of either FDC. Similarly, there was no evidence of a
negative impact of either FDC on clinical laboratory
findings.
An important feature of the present study is that, in
addition to the monitoring of safety as routinely per-
formed in clinical studies, the possible effects of ASAQ
and AL on the impairment of hearing and the QTc
interval were evaluated. Audiometric assessments did
not detect any significant deleterious auditory effects in
normal hearing associated with either FDC given for 3
days in adult patients. A QTc prolongation was
observed in both treatment groups between day 0 and
day 3. The prolongation of the QTc interval observed in
patients experiencing malaria episode resulted probably
from a real effect of treatments on depolarization, as
well as from an interfering artefact due to fever resolu-
tion and its induced chronotropic effect, this later was
greater in the ASAQ group. It should be noted that no
cardiac adverse events occurred during the follow-up
period. No clinical impact was observed.
One of the limitations of this study was that provision
of highly effective FDC treatment in a moderate and
highly seasonal transmission area, such as this study
area, resulted in relatively few patients presenting with a
second or third episode of malaria. The safety evaluation
of repeated FDC use, therefore, is restricted in the pre-
sent study, but suggests that repeated use of FDC
ASAQ and AL in the clinical trial setting should present
no major safety issues. Nevertheless, there is a need for
more extensive systems of pharmacovigilance for FDC
ACT when it is regularly used in routine clinical prac-
tice [25]. Currently, adverse events often go unreported
in routine clinical practice [26,27]. Health-care workers
are often unfamiliar with formal reporting procedures,
and tend to consider that the costs and additional work-
load outweigh any benefits. Improving voluntary phar-
macovigilance reporting in malaria-endemic areas of
Africa requires the active participation of patients and
health-care workers, and should encompass both public
and private sectors. Another challenge is to ensure the
reliability and validity of data generated by community
health-care workers for a community-based pharmacov-
igilance system.
Conclusions
Once-daily ASAQ FDC is non-inferior to twice-daily AL
FDC for the treatment of uncomplicated P. falciparum
malaria. The ACPR was unaffected by the patient’sa g e ,
being equally effective in patients <12 and ≥12 years of
age, and the number of malaria episodes experienced dur-
ing the study. The clinical safety profiles of ASAQ FDC
and AL FDC were comparable, and recurrent administra-
tion of ASAQ FDC did not result in major safety issues.
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